Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $291.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective hoisted by stock analysts at Barclays from $236.00 to $291.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s target price suggests a potential upside of 18.69% from the stock’s current price.

Several other analysts have also recently commented on the stock. Needham & Company LLC lifted their price objective on shares of Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the company a “buy” rating in a research note on Monday. BMO Capital Markets reaffirmed an “outperform” rating and set a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $283.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, June 21st. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Finally, Evercore ISI lifted their target price on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday. Eight equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $242.52.

Alnylam Pharmaceuticals Trading Up 2.1 %

Shares of NASDAQ ALNY opened at $245.17 on Tuesday. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $249.33. The company has a 50 day simple moving average of $155.86 and a two-hundred day simple moving average of $163.65. The stock has a market cap of $31.01 billion, a price-to-earnings ratio of -91.48 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. During the same quarter in the previous year, the firm posted ($1.40) earnings per share. The business’s revenue was up 54.8% on a year-over-year basis. Analysts forecast that Alnylam Pharmaceuticals will post -3.75 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $276,726.02. Following the completion of the sale, the executive vice president now owns 14,181 shares of the company’s stock, valued at $3,275,669.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $276,726.02. Following the completion of the sale, the executive vice president now owns 14,181 shares of the company’s stock, valued at $3,275,669.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Yvonne Greenstreet sold 8,301 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the sale, the chief executive officer now directly owns 80,534 shares of the company’s stock, valued at approximately $18,602,548.66. The disclosure for this sale can be found here. Insiders sold 67,357 shares of company stock valued at $13,436,711 over the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ALNY. Harbor Capital Advisors Inc. lifted its position in Alnylam Pharmaceuticals by 1.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock valued at $562,000 after buying an additional 51 shares during the last quarter. EP Wealth Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 6.4% during the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 71 shares in the last quarter. Commerce Bank lifted its position in shares of Alnylam Pharmaceuticals by 1.7% during the fourth quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock worth $896,000 after purchasing an additional 77 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in shares of Alnylam Pharmaceuticals by 7.0% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 89 shares in the last quarter. Finally, Metis Global Partners LLC lifted its position in shares of Alnylam Pharmaceuticals by 2.2% during the fourth quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company’s stock worth $839,000 after purchasing an additional 94 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.